Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

Elizabeth M. Swisher, Rebecca S. Kristeleit, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Howard A. Burris, Carol Aghajanian, David M. O'Malley, Alexandra Leary, Stephen Welch, Diane Provencher, Geoffrey I. Shapiro, Lee may Chen, Ronnie Shapira-Frommer, Scott H. Kaufmann, Sandra Goble, Lara Maloney, Tanya KwanKevin K. Lin, Iain A. McNeish

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib. Methods: This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed complete or partial response per RECIST were classified based on duration of response (DOR): long (≥1 year), intermediate (6 months to <1 year), or short (<6 months). Next-generation sequencing was used to detect deleterious mutations and loss of heterozygosity (LOH) in tumors. Results: Overall, 25.3% (138/545) of enrolled patients were responders. Of these, 27.5% (38/138) had long-term responses; 28.3% (39/138) were intermediate- and 34.8% (48/138) were short-term responders. Most of the long-term responders harbored a BRCA1 or BRCA2 (BRCA) mutation (71.1%, 27/38), and BRCA structural variants were most frequent among long-term responders (14.8%; 4/27). Responders with HGOC harboring a BRCA structural variant (n = 5) had significantly longer DOR than patients with other mutation types (n = 81; median not reached vs 0.62 years; HR, 0.21; 95% CI, 0.10–0.43; unadjusted p = 0.014). Among responders with BRCA wild-type HGOC, most long- and intermediate-term responders had high genome-wide LOH: 81.8% (9/11) and 76.9% (10/13), respectively, including 7 with deleterious RAD51C, RAD51D, or CDK12 mutations. Conclusion: Among patients who responded to rucaparib, a substantial proportion achieved responses lasting ≥1 year. These analyses demonstrate the relationship between DOR to PARP inhibitor treatment and molecular characteristics in HGOC, such as presence of reversion-resistant BRCA structural variants.

Original languageEnglish (US)
JournalGynecologic oncology
DOIs
StateAccepted/In press - 2021

Keywords

  • Duration of response
  • Genomics
  • Ovarian carcinoma
  • Rucaparib
  • Safety

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this